Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GPCR - US86366E1064 - ADR

69.36 USD
+0.75 (+1.09%)
Last: 1/12/2026, 8:00:01 PM
69.36 USD
0 (0%)
After Hours: 1/12/2026, 8:00:01 PM
Fundamental Rating

3

Taking everything into account, GPCR scores 3 out of 10 in our fundamental rating. GPCR was compared to 190 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for GPCR as it has an excellent financial health rating, but there are worries on the profitability. GPCR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GPCR had negative earnings in the past year.
In the past year GPCR has reported a negative cash flow from operations.
GPCR had negative earnings in each of the past 5 years.
GPCR had a negative operating cash flow in each of the past 5 years.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of GPCR (-25.32%) is comparable to the rest of the industry.
The Return On Equity of GPCR (-27.36%) is better than 62.11% of its industry peers.
Industry RankSector Rank
ROA -25.32%
ROE -27.36%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

GPCR has more shares outstanding than it did 1 year ago.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

GPCR has an Altman-Z score of 39.90. This indicates that GPCR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GPCR (39.90) is better than 93.68% of its industry peers.
There is no outstanding debt for GPCR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 39.9
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 14.15 indicates that GPCR has no problem at all paying its short term obligations.
GPCR has a Current ratio of 14.15. This is amongst the best in the industry. GPCR outperforms 84.21% of its industry peers.
A Quick Ratio of 14.15 indicates that GPCR has no problem at all paying its short term obligations.
GPCR has a better Quick ratio (14.15) than 84.21% of its industry peers.
Industry RankSector Rank
Current Ratio 14.15
Quick Ratio 14.15
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for GPCR have decreased strongly by -24.47% in the last year.
EPS 1Y (TTM)-24.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.45% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y39.79%
EPS Next 2Y12.38%
EPS Next 3Y5.71%
EPS Next 5Y19.45%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
Also next year GPCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.38%
EPS Next 3Y5.71%

More info and screens

0

5. Dividend

5.1 Amount

GPCR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (1/12/2026, 8:00:01 PM)

After market: 69.36 0 (0%)

69.36

+0.75 (+1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners84.19%
Inst Owner Change-0.05%
Ins Owners2.51%
Ins Owner Change-0.41%
Market Cap4.21B
Revenue(TTM)N/A
Net Income(TTM)-210.69M
Analysts87
Price Target94.31 (35.97%)
Short Float %25.37%
Short Ratio3.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-143.57%
Min EPS beat(2)-283.91%
Max EPS beat(2)-3.22%
EPS beat(4)0
Avg EPS beat(4)-184.08%
Min EPS beat(4)-283.91%
Max EPS beat(4)-3.22%
EPS beat(8)0
Avg EPS beat(8)-182.79%
EPS beat(12)1
Avg EPS beat(12)-139.89%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)21.89%
PT rev (3m)21.91%
EPS NQ rev (1m)-1.9%
EPS NQ rev (3m)-3.67%
EPS NY rev (1m)0.34%
EPS NY rev (3m)-4.63%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.47
P/tB 5.47
EV/EBITDA N/A
EPS(TTM)-2.95
EYN/A
EPS(NY)-1.77
Fwd EYN/A
FCF(TTM)-3.24
FCFYN/A
OCF(TTM)-3.2
OCFYN/A
SpS0
BVpS12.69
TBVpS12.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -25.32%
ROE -27.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 178.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.15
Quick Ratio 14.15
Altman-Z 39.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%38.33%
EPS Next Y39.79%
EPS Next 2Y12.38%
EPS Next 3Y5.71%
EPS Next 5Y19.45%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-74.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-75.14%
EBIT Next 3Y-35.19%
EBIT Next 5Y-11.31%
FCF growth 1Y-177.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-178.35%
OCF growth 3YN/A
OCF growth 5YN/A

STRUCTURE THERAPEUTICS INC / GPCR FAQ

What is the ChartMill fundamental rating of STRUCTURE THERAPEUTICS INC (GPCR) stock?

ChartMill assigns a fundamental rating of 3 / 10 to GPCR.


What is the valuation status of STRUCTURE THERAPEUTICS INC (GPCR) stock?

ChartMill assigns a valuation rating of 0 / 10 to STRUCTURE THERAPEUTICS INC (GPCR). This can be considered as Overvalued.


How profitable is STRUCTURE THERAPEUTICS INC (GPCR) stock?

STRUCTURE THERAPEUTICS INC (GPCR) has a profitability rating of 1 / 10.


What is the expected EPS growth for STRUCTURE THERAPEUTICS INC (GPCR) stock?

The Earnings per Share (EPS) of STRUCTURE THERAPEUTICS INC (GPCR) is expected to grow by 39.79% in the next year.